MPLT Chief Discovery Officer Anatol Kreitzer Sells $96K of Stock
Chief Discovery Officer Anatol Kreitzer unloaded 12,248 shares of MapLight Therapeutics, Inc. stock in a Form 4 filing.
Reviewed by automated data checks against the source filing. How we make and check alerts
Anatol Kreitzer, Chief Discovery Officer at MapLight Therapeutics, Inc. ($MPLT), sold 12,248 shares at an average price of $7.84, worth about $96,024.32, on October 15, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $MPLT is down 4.0% to date (from the $8.02 close on Oct 15, 2026).
MPLT
MapLight Therapeutics, Inc.
Key Points
- MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer sold 12,248 shares of stock at a price of $7.84 per share on October 15, 2026.
- After the trade, Anatol Kreitzer holds 168,678 $MPLT shares, down 6.77% from before the trade.
- Institutional funds like Novo Holdings A/S and FCPM III Services B.V. held steady positions in earlier reports.
- The clinical-stage biotech firm trades near its 52-week low ahead of its next earnings update on November 12, 2026.
Get $MPLT trade alerts by text
We text you when insiders, Congress or big funds trade $MPLT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated MapLight Therapeutics, Inc. alert may contain errors. Disclosures
MapLight Therapeutics, Inc. (NasdaqGS: MPLT) saw Chief Discovery Officer Anatol Kreitzer sell 12,248 shares of company stock on October 15, 2026, according to an SEC Form 4 filing.
Inside Anatol Kreitzer's MPLT Trade
Anatol Kreitzer unloaded 12,248 shares of stock on October 15, 2026, at a price of $7.84 per share. The transaction brought a total reported value of $96,024.32. The filing shows the sale was not part of a pre-arranged Rule 10b5-1 trading plan. The stock closed at $8.02 on the day of the transaction.
Other Institutional Activity in MapLight Therapeutics
Institutional investors hold sizable stakes in the clinical-stage biotech firm. Novo Holdings A/S held 3,686,622 shares valued at about $28,386,988 in its report for the period ended June 30, 2026, showing no change in share count. FCPM III Services B.V. kept its holding steady at 3,226,400 shares worth roughly $24,843,279. Nan Fung Group Holdings Limited maintained 971,253 shares valued at about $7,478,647. 5AM Venture Management, LLC held 950,011 shares worth roughly $7,315,084, while Sanofi kept 912,041 shares valued at about $7,022,715.
MapLight Therapeutics, Inc. Stock Down 3.9%
The shares recently traded around $7.71, sitting near the lower end of their 52-week range of $7.46 to $40.43. The recent price sits below both the 50-day moving average of $11.32 and the 200-day moving average of $21.04.
Recent Earnings
Recent reports show an EPS of -$6.25 over the trailing twelve months, with the next earnings release slated for November 12, 2026.
Insider Buying and Selling at MapLight Therapeutics, Inc.
Several company insiders have transacted in recent months, including earlier purchases by director Troy M. Cox and beneficial owner Catalyst4, alongside sales from other officers.
Analysts Set New Price Targets
Analyst firms covering the stock include Canaccord Genuity and Morgan Stanley, with a consensus recommendation leaning toward a strong buy.
About MapLight Therapeutics
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company based in Redwood City, California. The firm focuses on developing treatments for patients suffering from debilitating central nervous system disorders.
Bottom Line
Investors will watch for the company's upcoming earnings report on November 12, 2026, alongside any further ownership filings to gauge market sentiment.
Related Filing Alerts
Source: Anatol Kreitzer's Form 4 filing on $MPLT (Oct 15, 2026). Read the original filing: Form 4 filing on SEC EDGAR. Written by software, not financial advice. How we make alerts